Asia Pacific GMP Cell Therapy Consumables Market

The Asia Pacific GMP cell therapy consumables market is expected to grow from US$ 1,918.28 million in 2022 to US$ 9,093.86 million by 2028; it is estimated to grow at a CAGR of 29.6% from 2022 to 2028.

Increase in Strategic Collaborations Boosts Asia Pacific GMP Cell Therapy Consumables Market

The companies in the Asia Pacific GMP cell therapy consumables market is making strategic collaborations for the development of new products and cell therapy treatments. A few strategic collaborations in the GMP cell therapy consumables market are mentioned below:

• In October 2022, Pluristyx, panCELLa, and Implant Therapeutics management announced the corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technology and service offerings will accelerate the development and delivery of revolutionary cell therapies to patients.
• In June 2022, CellPoint and AboundBio entered into definitive agreements with Galapagos, propelling Galapagos into next-generation cell therapy while significantly broadening its portfolio and capabilities. The aim of this agreement is to expand the current market for CAR-T therapies and have an important impact on patients needing additional and improved treatment options.
• In November 2021, Laurus Labs signed an investment agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company, to acquire a 26.62% stake (fully diluted basis) for US$ 4.66, subject to the fulfillment of certain conditions.

Thus, the growing number of strategic collaborations among market players for the development of cell therapy has propelled the use of GMP cell therapy consumables to achieve the desired products, which drives the growth of the Asia Pacific GMP cell therapy consumables market.

Asia Pacific GMP cell therapy consumables Market Overview

The Asia Pacific GMP cell therapy consumables market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. The Asia Pacific GMP cell therapy consumables market growth is attributed to the growing pharmaceutical industry, a rising number of players in the region, an increasing number of regulations, and a rising awareness about cell therapy. China was the first country worldwide to approve gene therapy in 2003. However, developments in cell and gene therapy (CGT) were delayed due to a lack of clear and strict regulatory frameworks. The rapid advancements of CGTs' development worldwide and their therapeutic potential have triggered the government to conduct regulatory reforms to promote the normative development of CGTs in China. In 2017, the regulations regarding cell therapy were changed in such a manner that products of all cell therapy categories boomed. According to research conducted by Nature, approximately 953 cell and gene therapy clinical trials were initiated till March 2021, including Investigational New Drugs (IND), registered trials, and investigator-initiated trials (IITs). Encouraged by policy support, the remarkable progress for CGTs in China has been observed over the past few years, thereby making China a leading country in the development of CGTs.

Asia Pacific GMP Cell Therapy Consumables Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific GMP Cell Therapy Consumables Market Segmentation

The Asia Pacific GMP cell therapy consumables market is segmented on the basis of product, cell therapy, process, end use, and country.

• Based on product, the GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held the largest share of the market in 2022.
• Based on cell therapy, the GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. The T-cell therapy segment registered the largest share of the market in 2022.
• Based on process, the Asia Pacific GMP cell therapy consumables market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. The cell collection and characterization/sorting and separation segment held the largest share of the market in 2022.
• Based on end use, the Asia Pacific GMP cell therapy consumables market is segmented into clinical, commercial, and research. The clinical segment held the largest share of the market in 2022.
• Based on country, the Asia Pacific GMP cell therapy consumables market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.

Bio-Techne Corp, BPS Bioscience Inc, Corning Inc, FUJIFILM Irvine Scientific Inc, Global Life Sciences Solutions USA LLC, Lonza Group AG, Merck KGaA, Miltenyi Biotec BV & Co KG, Sartorius AG, and Thermo Fisher Scientific Inc are the leading companies operating in the Asia Pacific GMP cell therapy consumables market.

Asia Pacific GMP Cell Therapy Consumables Market Strategic Insights

Asia Pacific GMP Cell Therapy Consumables Market Segmentation Analysis

Asia Pacific GMP Cell Therapy Consumables Market Report Highlights

Asia Pacific GMP Cell Therapy Consumables Report Scope

Asia Pacific GMP Cell Therapy Consumables Market Country and Regional Insights